RaQualia Pharma Inc. (JP:4579)
:4579
4579 Stock Chart & Stats
¥1010.00
-¥6.00(-1.49%)
At close: 4:00 PM EST
¥1010.00
-¥6.00(-1.49%)
Day’s Range― - ―
52-Week Range¥301.00 - ¥1,465.00
Previous CloseN/A
Volume117.60K
Average Volume (3M)352.93K
Market Cap
¥20.28B
Enterprise Value¥19.94B
Total Cash (Recent Filing)¥3.24B
Total Debt (Recent Filing)¥2.90B
Price to Earnings (P/E)87.6
Beta0.91
Next Earnings
May 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)35.82
Shares Outstanding24,458,673
10 Day Avg. Volume795,170
30 Day Avg. Volume352,926
Financial Highlights & Ratios
PEG Ratio-0.58
Price to Book (P/B)3.47
Price to Sales (P/S)6.01
P/FCF Ratio-56.43
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)48.4
Revenue Forecast (FY)¥4.59B
Bulls Say, Bears Say
Bulls Say
Rebound In Profitability And Strong MarginsA 2025 return to positive EBIT and net income, paired with very high gross margins and ~31% revenue growth, indicates the business can scale income from its drug candidates. Durable high gross margins support reinvestment into R&D or partnerships and improve medium‑term earnings power if sustained.
Generally Sound Balance Sheet And Equity BaseAn increased equity base and a still-moderate debt-to-equity (~0.42) provide a financial cushion to absorb R&D spending and milestone-driven volatility. This capital structure supports continued licensing negotiations and selective internal development without immediate solvency pressure.
Capital-light Licensing/collaboration ModelA business model that monetizes drug candidates via upfronts, milestones and royalties reduces the need to fully fund late‑stage development and global commercialization. That structural model preserves cash, shares development risk with partners, and enables scalable revenue streams over the medium term.
Bears Say
Weak And Inconsistent Cash GenerationNegative operating and free cash flow in 2025, after prior periods of positive cash generation, shows the company struggles to convert accounting profits into cash consistently. That increases dependency on external financing or partner payments and can constrain R&D or commercialization investment over coming quarters.
Historically Volatile Earnings And Prior LossesA history of sizable losses and swingy earnings undermines predictability of future profitability and complicates long-term planning. Volatility can weaken negotiating leverage with partners, raise financing costs, and make sustained margin improvement harder to rely on across the investment cycle.
Rising Leverage And Low ROEMaterially higher leverage relative to prior near-zero debt increases fixed obligations and reduces financial flexibility. Coupled with a low ROE (~4%), this suggests capital currently generates weak returns, raising the risk that additional borrowing or equity raises will be needed and may be costly.
RaQualia Pharma Inc. News
4579 FAQ
What was RaQualia Pharma Inc.’s price range in the past 12 months?
RaQualia Pharma Inc. lowest stock price was ¥301.00 and its highest was ¥1465.00 in the past 12 months.
What is RaQualia Pharma Inc.’s market cap?
RaQualia Pharma Inc.’s market cap is ¥20.28B.
When is RaQualia Pharma Inc.’s upcoming earnings report date?
RaQualia Pharma Inc.’s upcoming earnings report date is May 20, 2026 which is in 53 days.
How were RaQualia Pharma Inc.’s earnings last quarter?
RaQualia Pharma Inc. released its earnings results on Feb 13, 2026. The company reported ¥35.82 earnings per share for the quarter, beating the consensus estimate of N/A by ¥35.82.
Is RaQualia Pharma Inc. overvalued?
According to Wall Street analysts RaQualia Pharma Inc.’s price is currently Overvalued.
Does RaQualia Pharma Inc. pay dividends?
RaQualia Pharma Inc. does not currently pay dividends.
What is RaQualia Pharma Inc.’s EPS estimate?
RaQualia Pharma Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does RaQualia Pharma Inc. have?
RaQualia Pharma Inc. has 24,458,673 shares outstanding.
What happened to RaQualia Pharma Inc.’s price movement after its last earnings report?
RaQualia Pharma Inc. reported an EPS of ¥35.82 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 2.207%.
Which hedge fund is a major shareholder of RaQualia Pharma Inc.?
Currently, no hedge funds are holding shares in JP:4579
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
RaQualia Pharma Inc.
RaQualia Pharma Inc. engages in the research and development of pharmaceutical compounds worldwide. Its human products portfolio includes tegoprazan for gastroesophageal reflux disease, which is in phase 1 clinical trial in the United States; and grapiprant for pain management, which is in phase II clinical trial in the United States and phase I clinical trial in China, as well as in phase I clinical trial in China and the United States to treat cancer. The company also provides veterinary products such as, grapiprant for osteoarthritis in dogs; ghrelin receptor agonist to treat cancer-related anorexia/cachexia syndrome, and constipation resulting from spinal cord injury; and ELURA, a drug for the management of weight loss in cats with chronic kidney disease. In addition, it provides TRPM8 blocker for the target indication of neuropathic pain; motilin receptor agonist to treat gastrointestinal dysmotility, including gastroparesis, functional dyspepsia, and post-operative ileus; potassium-competitive acid blocker to treat gastro-esophageal reflux disease that has completed phase 1 clinical trial; 5-HT4 partial agonist to treat gastroparesis, functional dyspepsia, and chronic constipation; 5-HT2B antagonist to treat irritable bowel syndrome with diarrhea; EP4 antagonist, a pain management drugs for dogs; serotonin 5-HT2A and dopamine D2 receptor blocker to treat schizophrenia; EP4 antagonist to treat cancer that is in phase I clinical trial, as well as in phase 1 clinical trial for the indication of pain; Cyclooxygenase-2 inhibitor, Phase I clinical trials for the indication of pain; CB2 agonist; selective sodium channel blocker; P2X7 receptor antagonist, which is in Phase I clinical trials for the target indication of neuropathic pain; and retinoic acid receptor alpha agonist. It has a collaborative agreement with Interprotein Corporation, ASKA Pharmaceutical. Co., Ltd., and Epigeneron, Inc. The company was incorporated in 2008 and is headquartered in Nagoya, Japan.